YCU PR Office, Author at Yokohama City University

2022-10-20

Global case fatality rate from COVID-19 has decreased by 96.8% during 2.5 years of the pandemic

We appreciate the commendable work by Wang et al.1 in evaluating the incidence and case fatality rate (CFR) of SARS-CoV-2 Delta and Omicron variants.

2022-10-12

Comparison of the blood pressure management between sodium glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists

The cardiovascular and renal protective effects of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide 1 receptor agonists (GLP-1Ras) are enhanced by low/controlled blood pressure (BP).

2022-09-26

Immune Checkpoint Inhibitors do not Increase Short-term Risk of Hypertension in Cancer Patients: A Systematic Literature Review and Meta-analysis

Background: Immune checkpoint inhibitors (ICIs) are becoming widely used for novel cancer treatments. Immune-related adverse events, including cardiac toxicity, are frequently observed following immune checkpoint inhibitor (ICI) use. However, little is known regarding the association between ICIs initiation and hypertension in cancer patients.

2022-09-13

Improved immune response to the third COVID-19 mRNA vaccine dose in hemodialysis patients

Introduction A third dose of SARS-CoV-2 mRNA vaccine has been administered in several countries.1,2 Patients with end-stage kidney disease have a weak immune response to 2-sessional doses of the mRNA vaccine.3, 4, 5, 6, 7 Because patients undergoing hemodialysis (HD) are at a high risk for COVID-19 severity and death, they have been prioritized in vaccination programs worldwide.8,9